Mineralys Therapeutics, Inc. (MLYS)
(Real Time Quote from BATS)
$13.36 USD
-0.05 (-0.37%)
Updated Aug 6, 2025 12:02 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MLYS 13.36 -0.05(-0.37%)
Will MLYS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MLYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MLYS
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect?
MLYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
Other News for MLYS
MLYS Crosses Below Key Moving Average Level
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference ...
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Insider Sell: Adam Levy Sells 73,678 Shares of Mineralys Therapeutics Inc (MLYS)
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)